The stock of Bluebird bio Inc (BLUE) has seen a 35.21% increase in the past week, with a -17.59% drop in the past month, and a -28.26% decrease in the past quarter. The volatility ratio for the week is 12.80%, and the volatility levels for the past 30 days are at 10.63% for BLUE. The simple moving average for the last 20 days is 6.48% for BLUE’s stock, with a simple moving average of -54.31% for the last 200 days.
Is It Worth Investing in Bluebird bio Inc (NASDAQ: BLUE) Right Now?
Company’s 36-month beta value is 0.73.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 6 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BLUE is 192.72M, and currently, short sellers hold a 22.64% ratio of that floaft. The average trading volume of BLUE on November 29, 2024 was 6.38M shares.
BLUE) stock’s latest price update
Bluebird bio Inc (NASDAQ: BLUE)’s stock price has gone rise by 6.62 in comparison to its previous close of 0.38, however, the company has experienced a 35.21% increase in its stock price over the last five trading days. reuters.com reported 2024-11-27 that The U.S. Food and Drug Administration said on Wednesday it is investigating reports of blood cancers in patients who were treated with bluebird bio’s gene therapy Skysona.
Analysts’ Opinion of BLUE
BofA Securities, on the other hand, stated in their research note that they expect to see BLUE reach a price target of $0.50, previously predicting the price at $3. The rating they have provided for BLUE stocks is “Neutral” according to the report published on November 15th, 2024.
BLUE Trading at -10.29% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.72% of loss for the given period.
Volatility was left at 10.63%, however, over the last 30 days, the volatility rate increased by 12.80%, as shares sank -14.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.29% lower at present.
During the last 5 trading sessions, BLUE rose by +33.30%, which changed the moving average for the period of 200-days by -61.26% in comparison to the 20-day moving average, which settled at $0.3780. In addition, Bluebird bio Inc saw -70.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLUE starting from Klima Thomas J, who sale 1,006 shares at the price of $0.53 back on Sep 30 ’24. After this action, Klima Thomas J now owns 170,000 shares of Bluebird bio Inc, valued at $529 using the latest closing price.
Obenshain Andrew, the President and CEO of Bluebird bio Inc, sale 34,780 shares at $0.53 during a trade that took place back on Sep 30 ’24, which means that Obenshain Andrew is holding 375,218 shares at $18,270 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -5.96 for the present operating margin
- -0.43 for the gross margin
The net margin for Bluebird bio Inc stands at -5.66. The total capital return value is set at -1.87. Equity return is now at value -270.20, with -54.29 for asset returns.
Based on Bluebird bio Inc (BLUE), the company’s capital structure generated 1.09 points at debt to capital in total, while cash flow to debt ratio is standing at -3.17. The debt to equity ratio resting at -12.2. The interest coverage ratio of the stock is -19.69.
Currently, EBITDA for the company is -167.16 million with net debt to EBITDA at -2.32. When we switch over and look at the enterprise to sales, we see a ratio of 7.09. The receivables turnover for the company is 3.71for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.51.
Conclusion
In a nutshell, Bluebird bio Inc (BLUE) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
